Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0JI4G
|
||||
Former ID |
DNC013896
|
||||
Drug Name |
Palodesangren E
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C31H28O7
|
||||
Canonical SMILES |
CC1=CC2C(C(C1)C3=C(C=C(C=C3)O)OC)C(OC4=C2C=C5C=CC(=O)OC<br />5=C4)C6=C(C=C(C=C6)O)OC
|
||||
InChI |
1S/C31H28O7/c1-16-10-23(20-7-5-18(32)13-26(20)35-2)30-24(11-16)22-12-17-4-9-29(34)37-25(17)15-28(22)38-31(30)21-8-6-19(33)14-27(21)36-3/h4-9,11-15,23-24,30-33H,10H2,1-3H3/t23-,24-,30-,31+/m0/s1
|
||||
InChIKey |
BKCPZBIJQGQCCP-ODJQGHGISA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Androgen receptor | Target Info | Inhibitor | [1] | |
KEGG Pathway | Oocyte meiosis | ||||
Pathways in cancer | |||||
Prostate cancer | |||||
NetPath Pathway | EGFR1 Signaling Pathway | ||||
AndrogenReceptor Signaling Pathway | |||||
FSH Signaling Pathway | |||||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
Coregulation of Androgen receptor activity | |||||
Regulation of Androgen receptor activity | |||||
Nongenotropic Androgen signaling | |||||
Regulation of nuclear beta catenin signaling and target gene transcription | |||||
FOXA1 transcription factor network | |||||
Notch-mediated HES/HEY network | |||||
Reactome | Nuclear Receptor transcription pathway | ||||
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | |||||
WikiPathways | SIDS Susceptibility Pathways | ||||
Integrated Pancreatic Cancer Pathway | |||||
Prostate Cancer | |||||
Integrated Breast Cancer Pathway | |||||
Nuclear Receptors | |||||
Androgen receptor signaling pathway | |||||
References | |||||
REF 1 | J Nat Prod. 1997 Oct;60(10):997-1002.Antiandrogenic natural Diels--Alder-type adducts from Brosimum rubescens. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.